Highest-materiality recent filing
Bioxytran reports first CIDP patient on PLICID shows functional gains; no adverse events
First CIDP patient treated with once-weekly IV PLICID regained finger use and ability to walk miles.
Bioxytran completes $1.2M private placement, issues 21.1M shares and 19.8M warrants
Gross proceeds of approximately $1.2 million from sale of 21,071,667 shares at $0.055 per share.
Bioxytran amends preferred stock conversion rights, grants CEO 6M preferred shares
Amendment requires both Board and majority of Preferred holders to approve any conversion of Convertible Preferred Stock into common shares.
Bioxytran's ProLectin-M achieves 90% Day-5 viral clearance in Phase 1b/2a COVID-19 study
Phase 1b/2a trial: 39 patients; highest dose 16,800 mg/day showed 90% Day-5 viral clearance vs 20% placebo (p=0.001).
Bioxytran signs distribution deal with Khoury Medical for A-SUQAR supplement
Agreement with Khoury Medical to commercialize A-SUQAR, a chewable blood sugar supplement using Bioxytran's PHGG formulation.
Bioxytran reports Phase 2 ProLectin-M shows 100% viral clearance at day 7; p=0.001
100% of treated subjects achieved complete viral clearance by Day 7 vs placebo (p=.001).
Bioxytran terminates Officer Mike Sheikh; Sheikh contests dismissal reason affecting severance
Mike Sheikh terminated as an Officer effective December 29, 2025.
Director resigns citing governance concerns; Bioxytran hires independent expert for controls review
Anders Utter resigns from Bioxytran's Board and Audit Committee chair, effective Dec 7, 2025, citing need for enhanced oversight and controls.
Bioxytran acquires NDPD Pharma in $15.85M stock deal; CFO adopts 10b5-1 plan
Acquired 100% of NDPD Pharma for 3,389,169 common shares and 28,467,564 preferred shares valued at ~$12.46M.
Bioxytran secures $1.6M stock purchase with Triton Funds; management forfeits $460K salaries
Triton Funds LP commits up to $1.6M for up to 17.5M shares (19.9%) at lowest traded price 10 days prior to closing.
BioXytran restates 2022-2023 financials on share valuation errors; non-reliance on prior filings
Net loss for 2023 increased by $192,523 to $4.56M; for 2022 increased by $9,202 to $2.67M.
Bioxytran publishes preprint on galectin-3's role in ICI resistance and potential enhancement
Preprint reviews theories that galectin-3 contributes to ICI resistance; galectin-3 antagonists may reverse effect.
Bioxytran acquires NDPD Pharma for $15.85M in stock; CFO adopts 10b5-1 plan
Acquired 100% of NDPD Pharma for stock: 3.39M common shares at $0.109 and 28.47M preferred shares at $0.543.
Bioxytran issues 28.97M preferred shares to insiders, converts 94M common shares and $354K debt
Issued 28,971,248 convertible preferred shares to insiders in exchange for 94,057,658 common shares at a 5:1 ratio.
Bioxytran launches JV with Heme Foundation for universal oxygen carrier; up to $10M pledged
JV with Heme Foundation and NDPD Pharma to develop Universal Oxygen Carrier (UOC) as blood substitute.
Bioxytran announces Springer book linking hyperbaric oxygenation to BXT-25 drug
Book by Prof. Mayevsky published by Springer; covers hyperbaric oxygenation and mitochondrial activity.
Bioxytran dismisses BF Borgers, appoints Fruci & Associates as new auditor
Dismissed BF Borgers CPA PC as independent auditor effective May 7, 2024.
Board designated 49.5M of 50M authorized preferred shares as Convertible Preferred Stock with 10 votes per share on as-converted basis.
Bioxytran receives FDA clearance to initiate clinical trials for ProLectin-M in COVID-19
FDA cleared IND No. 153742 for ProLectin-M, an oral galectin antagonist for mild-to-moderate COVID-19.
Bioxytran secures $500k equity investment from Triton Funds for COVID-19 trial funding
Triton Funds LP to purchase 1,612,903 shares at $0.31/share, totaling $500,000.
Board dismissed Pinnacle Accountancy Group and engaged BF Borgers CPA PC as independent auditor, effective March 6, 2023.
Bioxytran receives CDSCO approval for first-in-human ProLectin-I trial
India's CDSCO granted IND authorization (CT-06, No. CT/ND/03/2023) to evaluate ProLectin-I injection.
Wholly owned subsidiary Pharmalectin India Private Limited registered on Sept 7, 2022 in India.
Bioxytran receives CDSCO approval for Phase 1b/2a trial of ProLectin-M in COVID-19 patients
IND authorization from India's CDSCO for a Phase 1b/2a randomized, blinded, placebo-controlled study of ProLectin-M in mild-to-moderate COVID-19.
Bioxytran Phase 2 trial of ProLectin-M shows 100% viral clearance at day 7 in COVID-19 patients
100% of treated patients achieved viral clearance by day 7 vs 6% placebo (p=.001); 88% by day 3 vs 0% placebo.
Bioxytran modifies officer severance terms after $1.27M salary forfeiture
Officers forfeited $1,273,000 in accrued salaries and benefits on Aug 1, 2022.
Bioxytran raises $600K in private placement for Covid-19, lung fibrosis clinical trials
Issued 1.4M shares at $0.4286/share to an accredited investor for gross proceeds of $600,000.
Bioxytran publishes positive peer-reviewed data for ProLectin-M and PLG-007 drug candidates
August 1, 2022 article in Int. J. Health Sciences: ProLectin-M blocks SARS-CoV-2 in vitro; all 5 COVID-19 patients achieved complete remission, zero hospitalization.
PCT published patent WO 2022/099052 for polysaccharides treating SARS-CoV-2, filed Nov 2021.
Entered 34 Note Purchase Agreements for $1,467,000 principal in convertible notes due Jan 10, 2023; 6% interest, conversion at $0.25/share.
Bioxytran director Henry Esber resigns; Hana Chen-Walden appointed to board
Dr. Henry Esber resigned as director effective July 15, 2021, for medical reasons.
Effective as of April 19, 2024, the Company has elected Dr. Radka Milanova, to fill the vacancy left by Dr. Chen-Walden, (now deceased).
Effective as of July 15, 2021, Dr. Henry Esber resigned as a Director of Bioxytran, Inc. (the “Company”) for medical reasons.
The Company elected Hana Chen-Walden, currently a member of the Company’s Medical Advisory Board, to fill the vacancy created by Dr. Esber’s resignation.
Max materiality 0.90 · Median 0.60 · Most common event other_material